Introduction
============

Acute renal failure (ARF) is one of the most common problems of the critical patient, often resulting in acute tubular necrosis following an impairment in renal hemodynamics. Fenoldopam is a selective dopaminergic agonist specific for dopaminergic receptor DA-1 that, provoking an increase in renal blood flow, diuresis and natriuresis, seems to prevent ARF -- exerting a nephro-protective effect.

Methods
=======

Patients in the ICU without ARF but at risk of renal damage (sepsis, nephrotoxic drug administration) were recruited. Fenoldopam was administered by intravenous infusion (0.05--0.1 μg/kg/min) for 24 hours. Specific tubular enzymatic biomarkers (β~2~-microglobulin, microalbuminuria, retinal binding protein, γGT, alkaline phosphatase, *n*-acetyl-glucosaminidase) have been dosed in urine before fenoldopam administration (basal value), at the end of the infusion (T1) and 24 hours later (T2). Diuresis, blood creatinine and cystatin C were also measured in the same interval. All data were compared using a *t*test and logistic regression analysis.

Results
=======

See Figure [1](#F1){ref-type="fig"}. Of the 23 patients studied, after informed written consent, 10 patients received fenoldopam. At T1 a statistically significant reduction of the tubular biomarkers, cystatin C and creatinine, and an increase in diuresis were found compared with basal. At T2 a nonstatistically significant reduction of γGT and microalbumin and cystatin C associated with an increased urinary output were observed, showing a benefit on kidney function lasting even after 48 hours.
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Conclusion
==========

Our study shows a significant protective effect of fenoldopam measured by tubular biomarkers after a 24 hour infusion.
